scholarly journals Efficacy of IVIG (Intravenous Immunoglobulin) for Corona Virus Disease 2019 (COVID-19): a meta-analysis

2021 ◽  
pp. 107732
Author(s):  
Huai-rong Xiang ◽  
Xuan Cheng ◽  
Yun Li ◽  
Wen-wen Luo ◽  
Qi-zhi Zhang ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Virus Disease ◽  
Meta Analysis ◽  
Corona Virus

scholarly journals Prevalence and risks of severe events for cancer patients with COVID-19 infection: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Qiang Su ◽  
Jie-xuan Hu ◽  
Hai-shan Lin ◽  
Zheng Zhang ◽  
Emily C. Zhu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Virus Disease ◽  
Meta Analysis ◽  
Corona Virus ◽  
Total Prevalence ◽  
Number Of Patients ◽  
Foundation Program ◽  
Novel Coronavirus ◽  
Epidemiological Characteristics ◽  
Prevalence Of Cancer

SummaryBackgroundThe corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases. In this meta-analysis, we studied the prevalence of cancer among patients with COVID-19 infection and their risks of severe events.MethodsWe searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics. We extracted data following PICO (patient, intervention, comparison and outcome) chart. Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data. We assessed the studies’ risk of bias in accordance to the adjusted Joanna Briggs Institute. We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects.FindingsOut of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19. The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer rate (0.29%) in China. Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China. The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China. The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19), hypertension (OR 1.27; 95% CI, 0.35 to 4.62; p=0.13), and respiratory diseases (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45).InterpretationThis comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer patients. Awareness of this could help guide clinicians and health policy makers in combating cancer in the context of COVID-19 pandemic.FundingBeijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ202010025047).

scholarly journals Risk factors for severe corona virus disease 2019 (COVID-19) patients : a systematic review and meta analysis

2020 ◽  
Author(s):  
Lizhen Xu ◽  
Yaqian Mao ◽  
Gang Chen
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Virus Disease ◽  
Meta Analysis ◽  
High Body Mass Index ◽  
Elderly Male ◽  
Corona Virus ◽  
Laboratory Test Results ◽  
Male Patients ◽  
Underlying Diseases

AbstractImportanceWith the increasing number of infections for COVID-19, the global health resources are deficient. At present, we don’t have specific medicines or vaccines against novel coronavirus pneumonia (NCP) and our assessment of risk factors for patients with severe pneumonia was limited. In order to maximize the use of limited medical resources, we should distinguish between mild and severe patients as early as possible.ObjectiveTo systematically review the evidence of risk factors for severe corona virus disease 2019 (COVID-19) patients.Evidence ReviewWe conducted a comprehensive search for primary literature in both Chinese and English electronic bibliographic data bases including China National Knowledge Infrastructure (CNKI), Wanfang, Weipu, Chinese Biomedicine Literature Database (CBM-SinoMed), MEDLINE (via PubMed), EMBASE, Cochrane Central Register, and Web of science. The American agency for health research and quality (AHRQ) tool were used for assessing risk of bias. Mata-analysis was undertaken using STATA version 15.0.Results20 articles (N=4062 participants) were eligible for this systematic review and meta-analysis. First in this review and meta-analysis, we found that elderly male patients with a high body mass index, high breathing rate and a combination of underlying diseases (such as hypertension, diabetes, cardiovascular disease, and chronic obstructive pulmonary disease) were more likely to develop into critically ill patients. second, compared with ordinary patients, severe patients had more significant symptom such as fever and dyspnea. Besides, the laboratory test results of severe patients had more abnormal than non-severe patients, such as the elevated levels of white-cell counts, liver enzymes, lactate dehydrogenase, creatine kinase, c-reactive protein and procalcitonin, etc, while the decreased levels of lymphocytes and albumin, etc.InterpretationThis is the first systematic review investigating the risk factors for severe corona virus disease 2019 (COVID-19) patients. The findings are presented and discussed by different clinical characteristics. Therefore, our review may provide guidance for clinical decision-making and optimizes resource allocation.Key PointsQuestionWhat are the risk factors for severe patients with corona virus disease 2019 (COVID-19)?FindingsFirst in this review and meta-analysis, we found that elderly male patients with a high body mass index, high breathing rate and a combination of underlying diseases were more likely to develop into critically ill patients. second, compared with ordinary patients, severe patients had more significant symptom such as fever and dyspnea. Last, we also found that the laboratory test results of severe patients had more abnormal than non-severe patients.MeaningThis review summaried the risk factors of severe COVID-19 patients and aim to provide a basis for early identification of severe patients by clinicians.

scholarly journals Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis

2020 ◽  
Vol 127 ◽  
pp. 104371 ◽  
Author(s):  
Yong Hu ◽  
Jiazhong Sun ◽  
Zhe Dai ◽  
Haohua Deng ◽  
Xin Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Virus Disease ◽  
Meta Analysis ◽  
Corona Virus

scholarly journals Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis

2020 ◽  
Vol 39 (3) ◽  
pp. 268-284 ◽  
Author(s):  
Ashish Kumar ◽  
Anil Arora ◽  
Praveen Sharma ◽  
Shrihari Anil Anikhindi ◽  
Naresh Bansal ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Course ◽  
Virus Disease ◽  
Meta Analysis ◽  
Corona Virus

Indikationen für chinesische Arzneimitteltherapie bei Covid-19-Erkrankungen

2020 ◽  
Vol 12 (03) ◽  
pp. 18-18
Author(s):  
Christian Thede
Keyword(s):  
Virus Disease ◽  
Traditionelle Chinesische Medizin ◽  
Chinesische Medizin ◽  
Corona Virus ◽  
Chinesische Arzneimitteltherapie

SummaryIn Reaktion auf den massiven Ausbruch von Covid-19-Erkrankungen in der Region Wuhan wurde von staatlicher Seite bereits Ende Januar 2020 eine Expertenkommission namhafter chinesischer TCM-Fachleute berufen. Nach der Sichtung einer größeren Anzahl von Patienten in Wuhan wurdenTherapieprotokolle für verschiedene Krankheitsstadien formuliert, die in den „Guidance for Corona Virus Disease 2019“ des Generalbüros der Nationalen Hygiene und Gesundheitskommission und des Büros der staatlichen Verwaltung für traditionelle chinesische Medizin aufgenommen wurden.

Sign in / Sign up

Export Citation Format

Share Document